477 related articles for article (PubMed ID: 31786560)
21. Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma.
Kebir S; Rauschenbach L; Gielen GH; Schäfer N; Tzaridis T; Scheffler B; Giordano FA; Lazaridis L; Herrlinger U; Glas M
J Clin Neurosci; 2018 Jul; 53():255-258. PubMed ID: 29754968
[TBL] [Abstract][Full Text] [Related]
22. Vessel Type Determined by Vessel Architectural Imaging Improves Differentiation between Early Tumor Progression and Pseudoprogression in Glioblastoma.
Kim M; Park JE; Emblem K; Bjørnerud A; Kim HS
AJNR Am J Neuroradiol; 2021 Apr; 42(4):663-670. PubMed ID: 33541891
[TBL] [Abstract][Full Text] [Related]
23. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
[TBL] [Abstract][Full Text] [Related]
24. Utility of Magnetic Resonance Perfusion Imaging in Quantifying Active Tumor Fraction and Radiation Necrosis in Recurrent Intracranial Tumors.
Shah AH; Kuchakulla M; Ibrahim GM; Dadheech E; Komotar RJ; Gultekin SH; Ivan ME
World Neurosurg; 2019 Jan; 121():e836-e842. PubMed ID: 30312826
[TBL] [Abstract][Full Text] [Related]
25. MRI and 11C-methyl-L-methionine PET Differentiate Bevacizumab True Responders After Initiating Therapy for Recurrent Glioblastoma.
Beppu T; Terasaki K; Sasaki T; Sato Y; Tomabechi M; Kato K; Sasaki M; Ogasawara K
Clin Nucl Med; 2016 Nov; 41(11):852-857. PubMed ID: 27648703
[TBL] [Abstract][Full Text] [Related]
26. Differentiation of Glioblastoma and Solitary Brain Metastasis by Gradient of Relative Cerebral Blood Volume in the Peritumoral Brain Zone Derived from Dynamic Susceptibility Contrast Perfusion Magnetic Resonance Imaging.
She D; Xing Z; Cao D
J Comput Assist Tomogr; 2019; 43(1):13-17. PubMed ID: 30015801
[TBL] [Abstract][Full Text] [Related]
27. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
[TBL] [Abstract][Full Text] [Related]
28. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
[TBL] [Abstract][Full Text] [Related]
29. Dynamic Contrast-Enhanced T1-Weighted Perfusion Magnetic Resonance Imaging Identifies Glioblastoma Immunohistochemical Biomarkers via Tumoral and Peritumoral Approach: A Pilot Study.
Ozturk K; Soylu E; Tolunay S; Narter S; Hakyemez B
World Neurosurg; 2019 Aug; 128():e195-e208. PubMed ID: 31003026
[TBL] [Abstract][Full Text] [Related]
30. Differentiation of progressive disease from pseudoprogression using 3D PCASL and DSC perfusion MRI in patients with glioblastoma.
Manning P; Daghighi S; Rajaratnam MK; Parthiban S; Bahrami N; Dale AM; Bolar D; Piccioni DE; McDonald CR; Farid N
J Neurooncol; 2020 May; 147(3):681-690. PubMed ID: 32239431
[TBL] [Abstract][Full Text] [Related]
31. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
[TBL] [Abstract][Full Text] [Related]
32. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
33. Differentiation of Recurrent Glioblastoma from Delayed Radiation Necrosis by Using Voxel-based Multiparametric Analysis of MR Imaging Data.
Yoon RG; Kim HS; Koh MJ; Shim WH; Jung SC; Kim SJ; Kim JH
Radiology; 2017 Oct; 285(1):206-213. PubMed ID: 28535120
[TBL] [Abstract][Full Text] [Related]
34. Recurrence of glioblastoma is associated with elevated microvascular transit time heterogeneity and increased hypoxia.
Stadlbauer A; Mouridsen K; Doerfler A; Bo Hansen M; Oberndorfer S; Zimmermann M; Buchfelder M; Heinz G; Roessler K
J Cereb Blood Flow Metab; 2018 Mar; 38(3):422-432. PubMed ID: 28273720
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral heterogeneity of oxygen metabolism and neovascularization uncovers 2 survival-relevant subgroups of IDH1 wild-type glioblastoma.
Stadlbauer A; Zimmermann M; Doerfler A; Oberndorfer S; Buchfelder M; Coras R; Kitzwögerer M; Roessler K
Neuro Oncol; 2018 Oct; 20(11):1536-1546. PubMed ID: 29718366
[TBL] [Abstract][Full Text] [Related]
36. Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme.
Bennett IE; Guo H; Kountouri N; D'abaco GM; Hovens CM; Moffat BA; Desmond P; Drummond K; Kaye AH; Morokoff AP
J Clin Neurosci; 2015 Nov; 22(11):1802-8. PubMed ID: 26308396
[TBL] [Abstract][Full Text] [Related]
37. Do perfusion and diffusion MRI predict glioblastoma relapse sites following chemoradiation?
Khalifa J; Tensaouti F; Lotterie JA; Catalaa I; Chaltiel L; Benouaich-Amiel A; Gomez-Roca C; Noël G; Truc G; Péran P; Berry I; Sunyach MP; Charissoux M; Johnson C; Cohen-Jonathan Moyal E; Laprie A
J Neurooncol; 2016 Oct; 130(1):181-192. PubMed ID: 27502603
[TBL] [Abstract][Full Text] [Related]
38. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas.
Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G
Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759
[TBL] [Abstract][Full Text] [Related]
39. Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.
Suh CH; Kim HS; Choi YJ; Kim N; Kim SJ
AJNR Am J Neuroradiol; 2013 Dec; 34(12):2278-86. PubMed ID: 23828115
[TBL] [Abstract][Full Text] [Related]
40. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
